Table 1 Characteristics of the patients with Takayasu arteritis (n = 42)
From: Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis
Variables | Value |
|---|---|
Qualitative variables, number (percent) | Â |
Sex, female:male | 39:3 |
Class of vascular involvement | Â |
1 | 4 (10%) |
2A | 4 (10%) |
2B | 3 (7%) |
3 | 1 (2%) |
4 | 0 |
5 | 30 (71%) |
Coronary involvement | 6 (14%) |
Pulmonary artery involvement | 13 (31%) |
Aneurysms | 16 (38%) |
Steroids | 30 (71%) |
Immunosuppressive therapy | 30 (71%) |
Azathioprine | 12 (29%) |
Methotrexate | 11 (26%) |
Mycophenolate | 4 (10%) |
Sirolimus | 2 (5%) |
Cyclophosphamide | 1 (2%) |
Biologic therapy | 19 (45%) |
TNF-blockers | 16 (38%) |
Tocilizumab | 2 (5%) |
Rituximab | 1 (2%) |
Active disease (National Institutes of Health criteria) | 12 (29%) |
Vascular enhancement (n = 30) | 5 (16%) |
Vascular progression (n = 40) | 9 (22%) |
Scalar variables, mean, median (range) | |
Age, years | 45, 46 (23 to 66) |
Age at disease onset, years | 33, 30 (17 to 56) |
Disease duration, years | 12, 10 (0 to 34) |
Prednisone (PDN) dose, mg/day (n = 30) | 9.2, 5 (3 to 35) |
Erythrocyte sedimentation rate, mm/h | 22, 15 (1 to 78) |
Serum C-reactive protein, mg/l | 6.2, 2.3 (0.1 to 40) |
Serum Pentraxin-3, ng/ml | 8.4, 5.5 (1.3 to 55) |